PROCEPT Slashes Guidance as Handpiece Sales Plunge 30%
PRCT is trading near its 52-week low of $16.665 (12% above the low).
Summary
PROCEPT BioRobotics cut its guidance after handpiece sales fell sharply in Q2–Q4 2025, with Q4 U.S. volume down 30% sequentially. The company cited over 10,000 units of excess customer inventory and the end of a bulk discount program as key drivers. UBS initiated coverage with a Neutral rating and a $20 price target, reflecting tempered expectations. This follows the company's Q1 report showing 20% revenue growth but widening losses and higher cash burn. The guidance cut signals deeper demand issues that could pressure the stock further.
At the time of this announcement, PRCT was trading at $18.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $16.67 to $51.38. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.